IPAMORELIN

Ipamorelin

Ipamorelin is a synthetic pentapeptide agonist of the growth hormone secretagogue receptor (GHS-R1a), the receptor later shown to bind the stomach hormone ghrelin. It was developed at Novo Nordisk in the 1990s (code NNC 26-0161) from the earlier GHRP-1 structure and was described in 1998 as the first selective growth hormone secretagogue, because in animal studies it released GH without the marked ACTH and cortisol responses seen with older GH-releasing peptides.

Product Specifications

• Product: Ipamorelin
• Amount: 5mg / 10mg
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Chemical Profile

• Compound class: Synthetic pentapeptide, ghrelin receptor (GHS-R1a) agonist
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (Aib = α-aminoisobutyric acid; D-2-Nal = D-2-naphthylalanine)
• Molecular formula: C₃₈H₄₉N₉O₅
• Molecular weight: 711.9 g/mol
• CAS number: 170851-70-4

What researchers study

Ipamorelin is used mainly as a selective tool ligand for the ghrelin receptor. Its short sequence contains three non-standard residues (Aib, D-2-naphthylalanine and D-phenylalanine), which give it stability and receptor specificity that native peptides lack.

• Receptor selectivity: the original characterization in rat pituitary cells and in swine compared Ipamorelin with GHRP-6, GHRP-2 and the non-peptide secretagogues, measuring GH release alongside ACTH, cortisol and prolactin.
• Bone and growth plate biology: rat studies examined longitudinal bone growth and growth plate changes as GH axis readouts.
• Pharmacokinetic and pharmacodynamic modeling: modeling work described the relationship between plasma peptide levels and GH response.
• Ghrelin receptor ligand design: Ipamorelin is a reference structure in medicinal chemistry reviews of peptide and peptidomimetic GHS-R1a agonists.
• Gastrointestinal motility: ghrelin receptor agonists are studied for their prokinetic effects in models of gut transit.

Regulatory status

Ipamorelin has been evaluated in clinical studies, and development for postoperative ileus was discontinued. It is not approved by the FDA. It is covered by the World Anti-Doping Agency’s Prohibited List under S2 (peptide hormones, growth factors, related substances and mimetics). It is sold here as a research reagent only.

Quality & Documentation

Every batch of Ipamorelin is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Research overview

For a longer look at Ipamorelin, covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our Ipamorelin research overview. It is written as background reading, and every study it cites is linked to PubMed.

Selected literature

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822
• Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID 10373343
• Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID 10496658
• Moulin A, et al. Recent developments in ghrelin receptor ligands. ChemMedChem. 2007;2(9):1242-1259. PMID 17520591
• Isidro ML, Cordido F. Growth hormone secretagogues. Comb Chem High Throughput Screen. 2006;9(3):175-180. PMID 16533150

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.